An interventional study of disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument in Uncontrolled Essential Hypertension, sponsored by Lepu Medical Technology (Beijing) Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-03.
Sponsored by Lepu Medical Technology (Beijing) Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Essential Hypertension with a site in China — 19 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.
Among the 76 studies in Essential Hypertension with a site in China, this one is the 65th largest by planned enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2023, is one of 22 with no phase, and was the 48th registered.
481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →19 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18–65
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–60 · Healthy volunteers
Suzhou Alphamab Co., Ltd. · Sites in China
Ages 18–65
Lepu Medical Technology (Beijing) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 18 · Phase 4 14
First in 2004; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 297 across the 67 interventional studies, 2,000 across the 9 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 76 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lepu Medical Technology (Beijing) Co., Ltd., one of the names counted as Lepu Medical. Under that name alone:
Lepu Medical Technology (Beijing) Co., Ltd. is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
Lepu Medical has 3 studies filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
5 of the studies in Essential Hypertension with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07191899Suzhou Alphamab Co., Ltd.To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension | 2026-12-30 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2027-01 |
| NCT07940075CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension . | 2027-01-31 |
| NCT07577323Xuanwu Hospital, BeijingSafety and Efficacy Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Modulation in Patients With Mild Essential Hypertension | 2027-05-31 |
| NCT07566650Xuanwu Hospital, BeijingHigh-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomized Controlled Trial | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 76 studies in Essential Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and feasibility of disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument in the treatment of essential hypertension.
Feasibility Research This is a prospective, small-sample, single-group study. A total of 10 subjects are planned to be included in this study. Disposable intravascular catheter and instrument are used for intravascular ultrasound ablation. All participants will be followed up by telephone or outpatient at 1, 2 and 6 months post-procedure, with procedural success rate as the primary endpoint. At the same time, the incidence of adverse events will be observed to make a preliminary evaluation of the safety and feasibility of disposable intravascular catheter and instrument, and to provide data support for the second-stage confirmatory study.
In feasibility research, statistical analysis of data will be performed after 30 days postoperative follow-up of the subjects, and the safety and feasibility of disposable intravascular catheter and instrument will be preliminarily evaluated before entering the stage of confirmatory trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive treatment from the disposable intravascular ultrasound ablation catheter.
Device: disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument
Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
Procedural success
Procedural success was defined as the absence of renal arterial related complication during the subject's hospitalization based on the device success.
Time frame: Before discharge (post-procedure), up to 7 days
Change in average 24-hour/night-time ambulatory Systolic Blood Pressure (SBP)
Time frame: 1 month, 2months, 6 months post-procedure
Change in average 24-hour/daytime/night-time ambulatory Diastolic Blood Pressure (DBP)
Time frame: 1 month, 2months, 6 months post-procedure
Change in average daytime ambulatory Systolic Blood Pressure (SBP)
Time frame: 1 month, 2months, 6 months post-procedure
Change in office systolic blood pressure
Time frame: 1 month, 2 months, 6 months post-procedure
Change in office diastolic blood pressure
Time frame: 1 month, 2 months, 6 months post-procedure
Device success
Time frame: immediate post-procedure
Incidence of achieving target office systolic blood pressure
Time frame: 1 month, 2 months, 6 months post-procedure
Significant embolic events resulting in end-organ damage
Time frame: 1 month, 2 months, 6 months post-procedure
Incidence of acute myocardial infarction, stroke, transient ischemic attack, cerebrovascular accident
Time frame: 1 month, 2 months, 6 months post-procedure
End-stage renal disease
Time frame: 1 month, 2 months, 6 months post-procedure
Renal artery or vascular complications requiring intervention
Time frame: 1 month, 2 months, 6 months post-procedure
Significant (50%) and severe (75%) new onset renal stenosis
Time frame: 6 months post-procedure
Severe access site complications
Time frame: 1 month, 2 months, 6 months post-procedure
Incidence of adverse events
Time frame: 1 month, 2 months, 6 months post-procedure
Stability of ultrasonic ablation instrument
Whether the instrument has failed during the use of the device, and whether the fault can be recovered.
Time frame: immediate post-procedure
Interface friendliness of ultrasonic ablation instrument
It is defined as whether the operation interface and difficulty of operation of the instrument are convenient.
Time frame: immediate post-procedure
Started Jan 2023 (actual). Primary completion is estimated for Dec 2023, 11 months after the start.
Of 80 interventional studies with no phase under Essential Hypertension, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lepu Medical Technology (Beijing) Co., Ltd. →